Sign in

Timothy Daley

Vice President and Senior Equity Research Analyst at Wells Fargo & Company/mn

Timothy Daley is a Vice President and Senior Equity Research Analyst at Wells Fargo in San Francisco, specializing in the Life Sciences sector. He covers major life sciences and analytical instrument companies including Thermo Fisher, and over 24 stocks overall, and he has a documented 52.94% success rate with an average return of 1.11% according to TipRanks and Benzinga performance metrics. Daley began his career prior to joining Wells Fargo, accumulating experience as a Senior Equity Research Analyst and has held the Vice President title at Wells Fargo, with a career notable for steady coverage and a moderate success ranking. He holds relevant professional credentials and securities licensing, and operates from Wells Fargo’s San Francisco office.

Timothy Daley's questions to CTLT leadership

Question · Q4 2023

Asked for specifics on the company's sterile fill/finish capacity, particularly for prefilled syringes. Also questioned why inventory balances haven't decreased yet despite supply chain normalization.

Answer

Close to 40% of the company's sterile fill/finish capacity is in prefilled syringes, and this is rapidly increasing to become the majority. Regarding inventory, management acknowledged it is a focus area. While receivables are easier to collect for quick cash, there is a significant opportunity to reduce inventory, which requires more process-oriented work that is now underway.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts